PBA
Paradigm Biocapital Advisors’s Ascendis Pharma ASND Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-664,307
| Closed | -$90.6M | – | 34 |
|
|
2024
Q2 | $90.6M | Buy |
664,307
+156,355
| +31% | +$21.3M | 3.47% | 11 |
|
|
2024
Q1 | $76.8M | Buy |
507,952
+156,252
| +44% | +$23.6M | 2.7% | 19 |
|
|
2023
Q4 | $44.3M | Buy |
+351,700
| New | +$44.3M | 2.07% | 17 |
|
|
2023
Q2 | – | Sell |
-350,866
| Closed | -$37.6M | – | 30 |
|
|
2023
Q1 | $37.6M | Sell |
350,866
-1,942
| -0.6% | -$208K | 3.57% | 16 |
|
|
2022
Q4 | $43.1M | Sell |
352,808
-144,539
| -29% | -$17.7M | 5.06% | 9 |
|
|
2022
Q3 | $51.4M | Buy |
497,347
+65,177
| +15% | +$6.73M | 6.85% | 4 |
|
|
2022
Q2 | $40.2M | Buy |
432,170
+110,549
| +34% | +$10.3M | 8.01% | 6 |
|
|
2022
Q1 | $37.7M | Buy |
321,621
+103,463
| +47% | +$12.1M | 9.98% | 1 |
|
|
2021
Q4 | $29.3M | Buy |
+218,158
| New | +$29.3M | 8.38% | 2 |
|